Literature DB >> 17629950

Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease.

Synthia H Mellon1, Wenhui Gong, Marcus D Schonemann.   

Abstract

The functions for neurosteroids during development and in response to nervous system injury are beginning to be identified. We focused on a mouse model in which we believed neurosteroid production would be altered, and which had a neurodegenerative phenotype. Niemann-Pick Type-C (NP-C) is an autosomal recessive neurodegenerative disease caused by mutations in NPC1 (95%) or NPC2 (5%), resulting in lysosomal accumulation of unesterified cholesterol and glycolipids. The NIH mouse model of NP-C has a mutation in the NPC1 gene, and exhibits several pathological features of the most severe NP-C patients. How lysosomal storage and trafficking defects lead to neurodegeneration is unknown. We found that these mice had normal neurosteroidogenic enzyme activity during development, but lost this activity in the early neonatal period, prior to onset of neurological symptoms. Neurons that expressed P450scc, 3beta HSD, as well as those that expressed 3alpha HSD and 5alpha reductase were lost in adult NP-C brains, resulting in diminished concentrations of allopregnanolone. We treated NP-C mice with allopregnanolone and found that a single dose in the neonatal period resulted in a doubling of life span, substantial delay in onset of neurological symptoms, survival of cerebellar Purkinje and granule cell neurons, and reduction in cholesterol and ganglioside accumulation. The mechanism by which allopregnanolone elicited these effects is unknown. Our in vitro studies showed that Purkinje cell survival promoted by allopregnanolone was lost by treatment with bicuculline, suggesting GABA(A) receptors may play a role. We treated NP-C mice with a synthetic GABA(A) neurosteroid, ganaxolone (3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one). Ganaxolone treatment of NP-C mice produced beneficial neurological effects, but these effects were not as robust as those obtained using allopregnanolone. Thus, allopregnanolone may elicit its effects through GABA(A) receptors and through other mechanisms. Additional studies also suggest that allopregnanolone may elicit its effects through pregnane-X-receptors (PXR). Our data suggest that mouse models of neurodegeneration may be beneficial in establishing both physiologic and pharmacologic actions of neurosteroids. These animal models further establish the wide range of functions of these compounds, which may ultimately be useful for treatment of human diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17629950      PMCID: PMC2323675          DOI: 10.1016/j.brainresrev.2007.05.012

Source DB:  PubMed          Journal:  Brain Res Rev        ISSN: 0165-0173


  128 in total

Review 1.  Organizing actions of neurosteroids in the Purkinje neuron.

Authors:  Kazuyoshi Tsutsui; Hirotaka Sakamoto; Hanako Shikimi; Kazuyoshi Ukena
Journal:  Neurosci Res       Date:  2004-07       Impact factor: 3.304

2.  Steroid 5alpha-reductase 1 promotes 5alpha-androstane-3alpha,17beta-diol synthesis in immature mouse testes by two pathways.

Authors:  Mala Mahendroo; Jean D Wilson; James A Richardson; Richard J Auchus
Journal:  Mol Cell Endocrinol       Date:  2004-07-30       Impact factor: 4.102

3.  Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex.

Authors:  Masatoshi Suzuki; Lynda S Wright; Padma Marwah; Henry A Lardy; Clive N Svendsen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

4.  Aberrant intracellular cholesterol transport disrupts pituitary and ovarian function.

Authors:  Nicolas Y Gévry; Flavia L Lopes; Sandra Ledoux; Bruce D Murphy
Journal:  Mol Endocrinol       Date:  2004-04-22

Review 5.  Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination.

Authors:  Michael Schumacher; Rachida Guennoun; Françoise Robert; Claude Carelli; Nathalie Gago; Abdel Ghoumari; Maria C Gonzalez Deniselle; Susana L Gonzalez; Chrystelle Ibanez; Florencia Labombarda; Héctor Coirini; Etienne-Emile Baulieu; Alejandro F De Nicola
Journal:  Growth Horm IGF Res       Date:  2004-06       Impact factor: 2.372

6.  Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone.

Authors:  Lisa D Griffin; Wenhui Gong; Lucie Verot; Synthia H Mellon
Journal:  Nat Med       Date:  2004-06-20       Impact factor: 53.440

Review 7.  Neurosteroids in the retina: neurodegenerative and neuroprotective agents in retinal degeneration.

Authors:  P Guarneri; C Cascio; D Russo; S D'Agostino; G Drago; G Galizzi; G De Leo; F Piccoli; M Guarneri; R Guarneri
Journal:  Ann N Y Acad Sci       Date:  2003-12       Impact factor: 5.691

Review 8.  Neurosteroid biosynthesis in the human brain and its clinical implications.

Authors:  Birgit Stoffel-Wagner
Journal:  Ann N Y Acad Sci       Date:  2003-12       Impact factor: 5.691

Review 9.  Pathogenesis in menstrual cycle-linked CNS disorders.

Authors:  Torbjörn Bäckström; Agneta Andersson; Lotta Andreé; Vita Birzniece; Marie Bixo; Inger Björn; David Haage; Monica Isaksson; Inga-Maj Johansson; Charlott Lindblad; Per Lundgren; Sigrid Nyberg; Inga-Stina Odmark; Jessica Strömberg; Inger Sundström-Poromaa; Sahruh Turkmen; Göran Wahlström; Mingde Wang; Anna-Carin Wihlbäck; Di Zhu; Elisabeth Zingmark
Journal:  Ann N Y Acad Sci       Date:  2003-12       Impact factor: 5.691

10.  Deletion of the mouse P450c17 gene causes early embryonic lethality.

Authors:  Susanna R Bair; Synthia H Mellon
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more
  42 in total

Review 1.  Pregnane xenobiotic receptors and membrane progestin receptors: role in neurosteroid-mediated motivated behaviours.

Authors:  C A Frye; C J Koonce; A A Walf
Journal:  J Neuroendocrinol       Date:  2013-11       Impact factor: 3.627

2.  Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease.

Authors:  Chenyou Sun; Xiaoming Ou; Jerry M Farley; Craig Stockmeier; Steven Bigler; Roberta Diaz Brinton; Jun Ming Wang
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

3.  Ischemic insult to cerebellar Purkinje cells causes diminished GABAA receptor function and allopregnanolone neuroprotection is associated with GABAA receptor stabilization.

Authors:  Melissa H Kelley; Noriko Taguchi; Ardalan Ardeshiri; Masayuki Kuroiwa; Patricia D Hurn; Richard J Traystman; Paco S Herson
Journal:  J Neurochem       Date:  2008-09-18       Impact factor: 5.372

Review 4.  Neurosteroids and GABAergic signaling in health and disease.

Authors:  Georgina MacKenzie; Jamie Maguire
Journal:  Biomol Concepts       Date:  2013-02

5.  Allopregnanolone Promotes Neuronal and Oligodendrocyte Differentiation In Vitro and In Vivo: Therapeutic Implication for Alzheimer's Disease.

Authors:  Shuhua Chen; Tian Wang; Jia Yao; Roberta Diaz Brinton
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

6.  Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.

Authors:  Jennifer C Naylor; Jason D Kilts; Christine M Hulette; David C Steffens; Dan G Blazer; John F Ervin; Jennifer L Strauss; Trina B Allen; Mark W Massing; Victoria M Payne; Nagy A Youssef; Lawrence J Shampine; Christine E Marx
Journal:  Biochim Biophys Acta       Date:  2010-05-19

7.  Role of pregnane xenobiotic receptor in the midbrain ventral tegmental area for estradiol- and 3α,5α-THP-facilitated lordosis of female rats.

Authors:  C A Frye; C J Koonce; A A Walf
Journal:  Psychopharmacology (Berl)       Date:  2014-01-17       Impact factor: 4.530

8.  Effects of the neuroactive steroid allopregnanolone on intracranial self-stimulation in C57BL/6J mice.

Authors:  A Leslie Morrow; C J Malanga; Eric W Fish; Buddy J Whitman; Jeff F DiBerto; J Elliott Robinson
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

Review 9.  Niemann-Pick disease type C.

Authors:  Marie T Vanier
Journal:  Orphanet J Rare Dis       Date:  2010-06-03       Impact factor: 4.123

10.  New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat.

Authors:  James E Wraith; Jackie Imrie
Journal:  Ther Clin Risk Manag       Date:  2009-11-18       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.